NOXXON Pharma N.V.: Noxxon Announces Manufacturing of NOX-A12 Drug Substance for Future Clinical Trials and Issuance of Convertible Bonds Under Financing Agreement With Atlas
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has received two batches of bulk NOX-A12 drug substance and has made additional manufacturing commitments. As such, NOXXON has drawn down additional financing tranches from its financing agreement with Atlas Special Opportunities, LLC (ASO), for a total consideration of €2.325 million, and issued 2,368 convertible bonds (including 43 convertible bonds issued in relation to the transaction fee) with a nominal value of EUR 1,000 each.
Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced
Ca bouge chez Visiomed , financements en fons propres depuis 2015 abcbourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abcbourse.com Daily Mail and Mail on Sunday newspapers.
(0.28)
Summary of operational events (more details are provided in the corresponding press releases available on Biophytis s website: www.biophytis.com)
Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19
In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations following COVID-19 infection;
Biophytis received approvals for COVA from the UK Medicines Healthcare Products Regulatory Agency (MHRA) in June 2020, from the United States Food and Drug Administration (FDA) and the French Health Authority (ANSM) in July 2020 and the Brazilian Health Regulatory Agency (ANVISA) in August 2020;